...
首页> 外文期刊>British Journal of Dermatology >Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate
【24h】

Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate

机译:活体角膜的日光光动力学疗法:一种随机双盲的非开发前瞻性预期研究,比较5-氨基乙酰乙酸纳米乳液(BF-200)与甲基-5-氨基乙酰乙酰乙酸酯

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives To compare the efficacy and adverse effects of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) with MAL in DL-PDT of grade I-III AKs.Summary Background Daylight-mediated photodynamic therapy (DL-PDT) using methyl-5-aminolaevulinate (MAL) is effective for thin, grade I, actinic keratoses (AK). There are no published studies of other photosensitizers used in DL-PDT.Methods In 13 patients, 177 AKs were randomized symmetrically for a split-face prospective observer-blinded study and received either BF-200 ALA or MAL DL-PDT. Grade I AKs were treated once and grade II-III AKs twice with a 0·25-mm layer of photosensitizer precursors. Pain was assessed during and after the daylight exposure. Efficacy at 3 months was assessed clinically and histologically.Results BF-200 ALA cleared 71/84 (84·5%) and MAL 69/93 (74·2%) of the AKs (P = 0·099), all grades responding equally, but with new AKs appearing during follow-up (n = 4, BF-200 ALA; n = 8, MAL). In per patient half-face analysis BF-200 ALA showed significantly higher clearance rates for grade I AKs than did MAL (P = 0·027), but for thicker grades, clearance was equal (P = 0·564). BF-200 ALA and MAL treatments resulted in 61·5% and 38·5% complete histological clearance (P = 0·375), respectively. p53 expression decreased by 54·4% and 33·7%, respectively (P = 0·552). Both treatments were nearly painless with similar adverse reactions and no difference in patient preference.Conclusions BF-200 ALA showed a trend towards improved efficacy results compared with MAL. Thicker lesions in both groups responded when treated repeatedly. Importantly, a thin 0·25-mm layer of the photosensitizer precursors was sufficient, which may lead to lower expense. What's already known about this topic? Daylight-mediated photodynamic therapy (DL-PDT) with methylaminolaevulinate (MAL) is effective for thin actinic keratoses (AK). What does this study add? 5-Aminolaevulinic acid nanoemulsion (BF-200 ALA) used as a 0·25-mm layer is at least as effective and well tolerated as is MAL in DL-PDT of AKs. Thicker AKs respond when treated repeatedly.
机译:目标,用于比较5-氨基乙酰乙酰丙烯酸纳米乳液(BF-200 ALA)与级I-III AKS等级DL-PDT的疗效和不利影响。使用甲基-5-静止背景日光介导的光动力治疗(DL-PDT)氨基纤维酸盐(MAL)对薄,I等级,光化角质(AK)是有效的。没有公开的研究DL-PDT中使用的其他光敏剂。在13名患者中,177个AKS对称随机,用于分裂面观察者盲化的研究,并接受BF-200 ALA或MAL DL-PDT。 I级AKS接受一次和级二级 - III AKS两次,具有0·25mm的光敏剂前体。在白天暴露期间和后评估疼痛。临床和组织学评估3个月的功效。结果BF-200 ALA清除了71/84(84·5%)和MAL 69/93(74·2%)的AKS(P = 0·099),所有等级响应同样,但随访期间出现的新的AKS(n = 4,BF-200 ALA; n = 8,MAL)。在每位患者的半脸分析中,BF-200 ALA显示出级别AKES的清除率明显高于MAL(P = 0·027),但对于较厚的等级,间隙等于(P = 0·564)。 BF-200 ALA和MAL治疗产生61·5%和38·5%完全的组织学间隙(P = 0·375)。 P53表达分别降低54·4%和33·7%(P = 0·552)。两种治疗与类似的不良反应几乎是无痛的,患者偏好没有差异。结论BF-200 ALA表现出改善疗效结果的趋势与MAL相比。两组中的较厚病变在反复处理时响应。重要的是,薄的0·25mm的光敏剂前体层足够,这可能导致较低的费用。这个主题已经知道了什么?具有甲基氨基酚素(MAL)的白天介导的光动力疗法(DL-PDT)对薄光纤维角膜(AK)有效。这项研究添加了什么?用作0·25毫米层的5-氨基乙酰硫酸纳米乳剂(BF-200Ala)至少与AKS的DL-PDT中的MAL一样有效且耐受性。更厚的AKs在反复治疗时响应。

著录项

  • 来源
    《British Journal of Dermatology》 |2014年第5期|共9页
  • 作者单位

    Department of Dermatology and Allergology Helsinki University Central HospitalHelsinki Finland;

    Department of Dermatology and Allergology P?ij?t-H?me Social Health Care GroupLahti Finland;

    Department of Dermatology and Allergology P?ij?t-H?me Social Health Care GroupLahti Finland;

    Department of Pathology P?ij?t-H?me Social and Health Care GroupLahti Finland;

    Department of Dermatology Tampere University Tampere University HospitalTampere Finland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病学与性病学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号